RB1 and neoplasm: Tumors with complete absence of CD8+ TILs were the least frequent in gBRCAvar with RB1 loss (4.1%) compared with the other groups (13.8% of gBRCAvar with retained RB1 tumor expression, 14.6% of gBRCAwt with RB1 tumor loss, and 18.8% of gBRCAwt with retained RB1 tumor expression).